Gardasil 9 (HPV9)

Overview

Gardasil 9 was developed by Merck Sharp & Dohme and approved by the FDA in December 2014 (BLA 125508), by the EMA in June 2015, and WHO-prequalified in September 2017. It supersedes the previous quadrivalent Gardasil (types 6/11/16/18), adding five additional high-risk oncogenic types (31/33/45/52/58) that together with types 16 and 18 account for approximately 90% of all cervical cancers worldwide.

HPV is the most common sexually transmitted infection globally — virtually all sexually active people will encounter HPV at some point. Of 200+ HPV types, 14 are classified as high-risk oncogenic types, causing ~570,000 new cervical cancer cases and ~311,000 deaths annually (WHO). Low-risk types 6 and 11 cause ~90% of genital warts. The vaccine's coverage of types 16, 18, 31, 33, 45, 52, and 58 is scientifically estimated to prevent approximately 90% of cervical cancer cases globally.

Population-level impact has been demonstrated in real-world registry data. A landmark Swedish national register study (Lei et al., NEJM 2020) found that vaccination before age 17 was associated with an 88% reduction in invasive cervical cancer incidence (adjusted RR 0.12, 95% CI 0.00–0.34) compared to unvaccinated women. In countries with high adolescent vaccination coverage — Australia, UK, Denmark — cervical cancer is projected to meet WHO elimination criteria (<4 per 100,000 age-standardized incidence) within a generation.

Platform & Antigen Design

HPV L1 VLP Architecture

  HPV L1 major capsid protein (9 types: 6, 11, 16, 18, 31, 33, 45, 52, 58)
  Each type expressed separately in Saccharomyces cerevisiae (yeast)
        │
        ▼
  L1 protein self-assembles into 55 nm VLPs
    72 L1 pentamers per VLP = 360 L1 monomers per particle
    No nucleic acid content — structurally identical to native HPV capsid surface
    No oncoproteins (E6/E7) — cannot cause cancer or replicate

  Formulated with AAHS adjuvant (amorphous aluminum hydroxyphosphate sulfate, 500 µg/dose)
    AAHS > alum: activates DCs more broadly, stronger NLRP3 + TLR4 signals

  IM injection
        │
        ├─ AAHS depot → slow antigen release + innate activation
        │    DC maturation → draining lymph node homing
        │
        ├─ VLP geometry: 360 L1 copies/particle → B-cell receptor crosslinking
        │    T-independent + T-dependent B-cell activation
        │    Germinal center reaction → affinity maturation → long-lived plasma cells
        │
        ├─ Anti-L1 IgG (type-specific; IgG1 + IgG4 dominant)
        │    Titers 5–50× higher than after natural HPV infection
        │
        └─ Correlate of protection: anti-L1 VLP neutralizing IgG
             Blocks HPV attachment to heparan sulfate proteoglycans + α6 integrin
             Prevents virion entry into cervical basal epithelium
             → Prevents integration → prevents oncogenic transformation

1. VLP multivalency: 360 L1 copies per 55 nm VLP creates an extremely high-density antigen display — crosslinks B-cell receptors far more effectively than soluble monomeric antigen, driving strong germinal center formation and affinity maturation.
2. No nucleic acid: VLPs contain no HPV DNA or RNA — cannot replicate, cannot integrate, cannot cause oncogenic transformation. This safety design is fundamental to the vaccine's acceptability.
3. AAHS adjuvant: Amorphous aluminum hydroxyphosphate sulfate activates NLRP3 inflammasome, TLR4, and other innate pathways more potently than crystalline alum, supporting the high-magnitude germinal center responses observed with Gardasil 9.
4. Type-specific neutralization: Anti-L1 IgG is strictly type-specific — antibodies against HPV16 L1 VLPs do not neutralize HPV18 or other types. Protection against each type is independent and requires the type's L1 VLP to be in the vaccine.
5. Persistence without boosters: Anti-L1 IgG titers to all 9 types remain detectable ≥12 years post-vaccination in prospective cohorts, with no evidence of immune memory failure in individuals who seroconverted on schedule.

Immunogenicity

Clinical Efficacy

Safety Profile

• Very Common Injection-site reactions — pain, swelling, erythema — pain in ~85%; swelling/erythema ~25%; onset within 1–2 days; self-limiting within 3–5 days. Most common reported adverse event; not associated with systemic reactions in isolation.
• Common Headache, fatigue, dizziness — ~10–15%; similar rates to other adolescent vaccines (Tdap, meningococcal).
• Uncommon Syncope (vasovagal) — ~2/100,000 doses; not vaccine-specific; occurs with all adolescent IM vaccines; standard 15-minute post-injection observation period recommended.
• Very Rare Anaphylaxis — ~1.7/1,000,000 doses; manageable with standard observation and epinephrine.
• Investigated / Not Established POTS, CRPS, fibromyalgia — extensively investigated following media reports; large controlled studies (EMA 2015, FDA VAERS analysis, multiple national registries) found no causal relationship; WHO GACVS: acceptable safety profile; benefits far outweigh risks.
• Pregnancy Not recommended during pregnancy (insufficient data); no adverse pregnancy outcomes documented in women inadvertently vaccinated while pregnant; resume after delivery.

Administration

Connections

References

• Joura EA, Giuliano AR, Iversen OE, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23. doi:10.1056/NEJMoa1405044 · PMID 25693011
• Lei J, Ploner A, Elfström KM, et al. HPV Vaccination and the Risk of Invasive Cervical Cancer. N Engl J Med. 2020;383(14):1340-1348. doi:10.1056/NEJMoa1917338 · PMID 33007079
• World Health Organization. Human papillomavirus vaccines: WHO position paper, December 2022. Wkly Epidemiol Rec. 2022;97(50):645-672. who.int/publications HPV position paper 2022